NT-proB natriuretic peptide, risk factors and asymptomatic left ventricular dysfunction: Results of the SCReening Evaluation of the Evolution of New Heart Failure Study (SCREEN-HF)

International Journal of Cardiology

Volumn 169, Issue 2, 2013, Pages 133-138

  McGrady, Michele ^a   Reid, Christopher M ^a   Shiel, Louise ^a   Wolfe, Rory ^a   Boffa, Umberto ^b   Liew, Danny ^c   Campbell, Duncan J ^d   Prior, David ^d   Stewart, Simon ^e   Krum, Henry ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Asymptomatic left ventricular dysfunction; Epidemiology; Heart failure; NT proBNP; Risk factors

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DIASTOLIC DYSFUNCTION; DISEASE COURSE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE FUNCTION; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INCIDENCE; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; OBESITY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCREENING TEST;

ASYMPTOMATIC LEFT VENTRICULAR DYSFUNCTION; EPIDEMIOLOGY; HEART FAILURE; NT-PROBNP; RISK FACTORS;

AGED; AGED, 80 AND OVER; ASYMPTOMATIC DISEASES; BIOLOGICAL MARKERS; COHORT STUDIES; DIASTOLE; EVOLUTION, MOLECULAR; FEMALE; HEART FAILURE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; QUESTIONNAIRES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84887104222     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.08.089     Document Type: Article

References (51)

1. M. McGrady, and H. Krum Screening: the new frontier in heart failure management Cardiovasc Ther 27 2009 1 3
2. Editorial Crunch time for heart failure care in England and Wales Lancet 376 2010 2041
3. T.A. McDonagh, C.E. Morrison, and A. Lawrence Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population Lancet 350 1997 829 833
4. M.K. Davies, F.D.R. Hobbs, and R.C. Davis Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study Lancet 358 2001 439 444
5. M.M. Redfield, S.J. Jacobsen, J.C. Burnett Jr., D.W. Mahoney, K.R. Bailey, and R.J. Rodeheffer Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic JAMA 289 2003 194 202
6. W.P. Abhayaratna, W.T. Smith, N.G. Becker, T.H. Marwick, I.M. Jeffery, and D.A. McGill Prevalence of heart failure and systolic ventricular dysfunction in older Australians: the Canberra Heart Study Med J Aust 184 2006 151 154
7. I. Hajjar, and T.A. Kotchen Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000 JAMA 290 2003 199 206
8. A.P. Kengne, F. Turnbull, and S. MacMahon The Framingham Study, diabetes mellitus and cardiovascular disease: turning back the clock Prog Cardiovasc Dis 53 2010 45 51
9. Dixon T, Waters AM. A growing problem: trends and patterns in overweight and obesity among adults in Australia, 1980 to 2001. Bulletin No. 8. AIHW. Cat. No. AUS 36. Canberra: AIHW, 2003.
10. V.L. Roger Heart disease and stroke statistics - 2011 update: a report from the American Heart Association Circulation 123 2011 e18 e209
11. SOLVD Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 325 1991 293 301
12. SOLVD Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions N Engl J Med 327 1992 685
13. P. Jong, S. Yusuf, M.F. Rousseau, S.A. Ahn, and S.I. Bangdiwala Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study Lancet 361 2003 1843 1848
14. A.M. Pritchett, D.W. Mahoney, S.J. Jacobsen, R.J. Rodeheffer, B.L. Karon, and M.M. Redfield Diastolic dysfunction and left atrial volume: a population-based study J Am Coll Cardiol 45 2005 87 92
15. R.C. Davis, F.D.R. Hobbs, and J.E. Kenkre Prevalence of left ventricular systolic dysfunction and heart failure in high risk patients: community based epidemiological study Brit Med J 325 2002 1156 1158
16. A.P. Davie, C.M. Francis, and M.P. Love Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction Brit Med J 312 1996 222
17. J.T. Thomas, R.F. Kelly, and S.J. Thomas Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure Am J Med 112 2002 437 445
18. P. Hedberg, I. Lonnberg, T. Jonason, G. Nilsson, K. Pehrsson, and I. Ringqvist Electrocardiogram and B-type natriuretic peptide as screening tools for left ventricular systolic dysfunction in a population-based sample of 75-year-old men and women Am Heart J 148 2004 524 529
19. B.M. Goudie, R.I. Jarvis, and P.T. Donnan Screening for left ventricular systolic dysfunction using GP-reported ECGs Brit J Gen Pract 57 2007 191 195
20. P.A. Heidenreich, M.A. Gubens, G.C. Fonarow, M.A. Konstam, L.W. Stevenson, and P.G. Shekelle Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction J Am Coll Cardiol 43 2004 1019 1026
21. O.W. Nielsen, T.A. McDonagh, S.D. Robb, and H.J. Dargie Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population J Am Coll Cardiol 41 2003 113 120
22. B.A. Groenning, I. Raymond, P.R. Hildebrandt, J.C. Nilsson, M. Baumann, and F. Pedersen Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population Heart 90 2004 297 303
23. M.R. Cowie, A.D. Struthers, and D.A. Wood Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care Lancet 350 1997 1349 1353
24. A.S. Maisel, P. Krishnaswamy, and R.M. Nowak Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure N Engl J Med 347 2002 161 167
25. P.A. McCullough, R.M. Nowak, and J. McCord B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study Circulation 106 2002 416 422
26. J.A. Doust, E. Pietrzak, A. Dobson, and P. Glasziou How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review Brit Med J 330 2005 625
27. T. Wang, G.L. Martin, L. Daniel, and J.B. Emelia Plasma natriuretic peptide levels and the risk of cardiovascular events and death N Engl J Med 350 2004 655 663
28. P. Porapakkham, P. Porapakkham, H. Zimmet, B. Billah, and H. Krum B-type natriuretic peptide-guided heart failure therapy: a meta-analysis Arch Intern Med. 170 2010 507 514
29. A. Maisel, J.E. Hollander, and D. Guss Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT): a multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath J Am Coll Cardiol 44 2004 1328 1333
30. J.G. Lainchbury, R.W. Troughton, and C.M. Frampton NTproBNP-guided drug treatment for chronic heart failure: design and methods in the BATTLESCARRED trial Eur J Heart Fail 8 2006 532 538
31. J. Latour-Perez, F.J. Coves-Orts, C. Abad-Terrado, V. Abraira, and J. Zamora Accuracy of B-type natriuretic peptide levels in the diagnosis of left ventricular dysfunction and heart failure: a systematic review Eur J Heart Fail 8 2006 390 399
32. R.V. Leupker, A. Evan, P. McKeigue, and K.S. Reddy Cardiovascular survey methods 2004 World Health Organisation Geneva
33. J. Gottdiener, J. Bednarz, and R. Devereux American Society of Echocardiography recommendations for use of echocardiography in clinical trials J Am Soc Echocardiogr 17 2004 1086 1119
34. S.R. Ommen, R.A. Nishimura, and C.P. Appleton Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler- catheterization study Circulation 102 2000 1788 1794
35. H. Baumgartner, J. Hung, and J. Bermejo Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice J Am Soc Echocardiogr 22 2009 1 23
36. W.A. Zoghbi, M. Enriquez-Sarano, and E. Foster Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography J Am Soc Echocardiogr 16 2003 777 802
37. National Heart Foundation of Australia (RF/RHD guideline development working group), and The Cardiac Society of Australia and New Zealand Diagnosis and management of acute rheumatic fever and rheumatic heart disease in Australia - an evidence based review 2006
38. L.K. Lin A concordance correlation coefficient to evaluate reproducibility Biometrics 45 1989 255 268
39. I. Betti, G. Castelli, and A. Barchielli The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF Study J Card Fail 15 2009 377 384
40. D. Atisha, M.A. Bhalla, and L.K. Morrison A prospective study in search of an optimal B-natriuretic peptide level to screen patients for cardiac dysfunction Am Heart J 148 2004 518 523
41. C. Mueller, A. Scholer, and K. Laule-Kilian Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea N Engl J Med 350 2004 647 654
42. H. Krum, M.V. Jelinek, S. Stewart, A. Sindone, and J.J. Atherton 2011 Update to NHF of Australia and CSANZ Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006 Med J Aust 194 2011 405 409
43. J. Koglin, S. Pehlivanli, M. Schwaiblmair, M. Vogeser, P. Cremer, and W. von Scheidt Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure J Am Coll Cardiol 38 2001 1934 1941
44. M.R. Cowie, P. Jourdain, and A. Maisel Clinical applications of B-type natriuretic peptide testing Eur Heart J 24 2003 1710 1718
45. L.L. Lam, P.A. Cameron, H.G. Schneider, M.J. Abramson, C. Mauller, and H. Krum Meta-analysis: effect of B-type natriuretic peptide testing on clinical outcomes in patients with acute dyspnea in the emergency setting Ann Intern Med 153 2010 728 735
46. T.A. McDonagh, A.D. Cunningham, and C.E. Morrison Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population Heart 86 2001 21 26
47. L.C. Costello-Boerrigter, and J.C. Burnett Jr. The prognostic value of N-terminal proB-type natriuretic peptide Nat Clin Pract Cardiovasc Med 2 2005 194 201
48. M. Nakamura, F. Tanaka, K. Sato, T. Segawa, and M. Nagano B-type natriuretic peptide testing for structural heart disease screening: a general population-based study J Card Fail 11 2005 705 712
49. L.N. Dyrbye, and M.M. Redfield The role of brain natriuretic peptide in population screening Heart Fail Rev 8 2003 349 354
50. L.L. Ng, I. Loke, and J.E. Davies Identification of previously undiagnosed left ventricular systolic dysfunction: community screening using natriuretic peptides and electrocardiography Eur J Heart Fail 5 2003 775 782
51. G. Murtagh, I.R. Dawkins, and R. O'Connell Screening to prevent heart failure (STOP-HF): expanding the focus beyond asymptomatic left ventricular systolic dysfunction Eur J Heart Fail 14 2012 480 486